2025 Asia Conference on Lung Cancer (ACLC)

This product is:

Free for conference attendees.
Available for purchase for those that did NOT attend the conference

For questions, email education@iasl.org.

The IASLC Asia Conference on Lung Cancer (ACLC), October 9-11, 2025 in Ho Chi Minh, Vietnam, will address key regional challenges, including the high prevalence of genetic mutations, environmental risk factors, and disparities in healthcare access. The conference will focus on expanding early detection through low-dose CT and AI, advancing biomarker testing, and fostering multidisciplinary collaboration among medical oncologists, surgeons, radiologists, pulmonologists, radiation oncologists, pathologists, and all healthcare providers involved in the care of patients with thoracic malignancies. Sessions will explore strategies to improve access to targeted therapies, immunotherapy, and innovative surgical and radiotherapy techniques. Additionally, discussions will highlight public health initiatives, tobacco control, and approaches to reduce healthcare disparities. Education, training, and patient advocacy will remain central themes, ensuring a sustainable and patient-centered approach to lung cancer care across Asia.

The conference is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to:

Examine scientific advances in thoracic cancer to make evidence-based diagnosis and treatment decisions.
Synthesize cutting edge research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
Support lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
Employ multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
Support and empower patients to become active participants in their treatment.

Program Co-Chairs:

Ying Chen, MD In Memoriam
Wendy Cooper, PhD, MB, FRCPA
Tu Dao, MD, PhD, FACP
Feng-Ming (Spring) Kong, MD, PhD
Jin Mo Goo, MD, PhD
Ayumi Suzuki, MD, PhD

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.